| Name | Title | Contact Details |
|---|---|---|
Jodie Morrison |
Chief Executive Officer | Profile |
Michael Curtis |
President and Chief Executive Officer | Profile |
Impact Biomedicines, Inc. (Impact) is pioneering the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers. Led by a highly skilled and devoted team, Impact is advancing a late-stage pipeline centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor, which is being developed initially for the treatment of myelofibrosis (MF) and polycythemia vera (PV). Impact was formed in 2016 after acquisition of Sanofi’s full rights for the global development and commercialization of fedratinib. The Impact team intends to pursue multiple clinical indications for fedratinib to maximize its potential as a best-in-class therapy for JAK2-dependent diseases.
Allylix Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Fraunhofer Center for Laser Technology is a Plymouth, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Vizgen is unlocking the power of spatial biomolecule profiling to bring new insight into biological systems and disease.
Center for Wound Healing is a Tarrytown, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.